Correction to: Allergy, Asthma & Clinical Immunology 17: 113 (2021) https://doi.org/10.1186/s13223-021-00614-6
Unfortunately, there is an error in a statement and two references were incorrectly cited. We would like to update the statement and the references as detailed below.
Corrections in original article [1]:
-
1.
Reference 55, Godse KV, Nadkarni NJ, Jani G, Ghate S. Fexofenadine in higher doses in chronic spontaneous urticaria. Indian Dermatol Online J. 2010;1(1):45–6. https://doi.org/10.4103/2229-5178.73262, does not support the statement. This reference has been replaced with the following: Estelle F & Simons R. The value of a broad therapeutic index for antihistamines. Adv Studies Med. 2002;2(24):872–876.
-
2.
Reference 56, Fexofenadine: https//www.drugs.com/pro/fexofenadine.html, also does not support the statement. This reference has been replaced with the following: Howarth PH. The concept of the therapeutic window in the choice of H1-receptor antagonist. Adv Studies Med. 2004;4(7):S508–512.
-
3.
To ensure that the statement is scientifically correct and aligns with the updated references 55 and 56, the following sentence ‘The established therapeutic range for fexofenadine in adults and children over 12 years is 20–240 mg’ has been replaced with ‘Fexofenadine has demonstrated a wide therapeutic index in adults and children over 12 years, with 20 mg twice daily the minimally effective dose, and no sedation or cardiac toxicity noted at 690 mg twice daily for 28 consecutive days’
Notes:
-
1.
The original references did not mention the therapeutic index for fexofenadine and were cited in error. The replacement references support the edited statement.
-
2.
The original statement was not scientifically accurate as it did not reflect the actual therapeutic index for fexofenadine. The suggested edits to the statement are supported by the replacement references.
Reference
Meltzer EO, Rosario NA, VanBever H, Lucio L. Fexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis. Allergy Asthma Clin Immunol. 2021;17:113. https://doi.org/10.1186/s13223-021-00614-6.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Meltzer, E.O., Rosario, N.A., Van Bever, H. et al. Correction: Fexofenadine: review of safety, efficacy and unmet needs in children with allergic rhinitis. Allergy Asthma Clin Immunol 18, 112 (2022). https://doi.org/10.1186/s13223-022-00754-3
Accepted:
Published:
DOI: https://doi.org/10.1186/s13223-022-00754-3